• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Study Identifies Trends Contributing to Clinical Trial Transformation

Study Identifies Trends Contributing to Clinical Trial Transformation

April 29, 2019
John Mitchell

A report from IQVIA has identified eight drivers of clinical development the company says will reach “peak impact” over the next two to four years.

  1. Digital health technologies will capture drug efficacy and safety data remotely to improve patient safety, enable virtual trial formats and ease site burdens.
  2. The availability of pre-screened patient pools and direct-to-patient recruitment will enable trials to meet enrollment targets, decrease trial duration and accelerate market availability.
  3. Predictive analytics and artificial intelligence technologies and methods will help identify new clinical hypotheses, reduce trial risk and speed enrollment by identifying protocol-ready patients.
  4. Increased focus on patient-reported outcomes will provide new insight into the patient experience, including drug efficacy and safety outside the clinical setting.
  5. Real-world data will contribute to all aspects of accelerating clinical trials, from optimizing trial design to site selection, and will drive real-world evidence registries and serve as a virtual control arm for trials.
  6. Use of targeted therapies and next-generation biotherapeutics — which have more than doubled over the past three years — also will speed trials and improve efficacy, as well as success rates. However, longer patient follow-up times will be required.
  7. Biomarker testing will be used more widely to better target trial patient populations. The field is expected to yield a 34 percent increase across therapy areas and trial phases, with a corresponding success rate of 27 percent.
  8. Regulatory support for precision medicine, as well as novel trial designs and endpoints, will contribute to accelerated drug approvals.

Read the full report at: https://bit.ly/2XK4OvA.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing